News & Events

Stay informed with crucial updates and upcoming NCODA events, where we champion innovations in cancer care and patient support.

Meetings

Webinars

Perspectives

Publications

News

NCODA Urges CMS to Reconsider Proposed QSSD Policy for Fixed-Combination New Formulations

NCODA has submitted comments to the Centers for Medicare & Medicaid Services (CMS) regarding its proposed policy for the treatment of certain fixed-combination new formulations under the Medicare Drug Price Negotiation Program.

News

Connecting clinical knowledge with care delivery: NCODA and Cureety partner to bring trusted regimen guidance at the point of care

NCODA and Cureety partner to integrate evidence-based Patient Education Sheets into oncology workflows, supporting patient-centered care.

News

Cortisol in Oncology: An Emerging Area of Scientific Inquiry

What role might stress biology play in cancer care? This article explores emerging research on glucocorticoid receptor (GR) signaling and its potential impact on tumor biology and treatment response.

News

NCODA Featured in Specialty Pharmacy Continuum on Medically Integrated Oncology Pharmacy

NCODA’s Jonas Congelli discusses the patient-care benefits and evolving future of medically integrated oncology pharmacy in Specialty Pharmacy Continuum.

News

NCODA Urges CMS to Reconsider Proposed QSSD Policy for Fixed-Combination New Formulations

NCODA has submitted comments to the Centers for Medicare & Medicaid Services (CMS) regarding its proposed policy for the treatment of certain fixed-combination new formulations under the Medicare Drug Price Negotiation Program.

News

NCODA and Leading Cancer Community Partners Issue Consensus Statementon U.S. Drug Shortages, Urge Policy Action

Today, NCODA, in partnership with organizations across the cancer community, released a consensus statement identifying the primary drivers of the persistent drug shortage crisis in the United States and proposing actionable policy solutions to protect access to…

White Paper

Universal DPYD Testing Prior to 5-FU and Capecitabine Therapy

This white paper outlines the clinical, economic, and policy rationale for universal DPYD testing prior to 5-FU and capecitabine therapy. Evidence shows that genotype-guided dosing prevents severe toxicities, reduces hospitalizations and healthcare costs, and al…

White Paper

Enhancing Oncology Care: The Role of Principal Illness Navigation in Improving Patient Outcomes

Patients with high-risk diseases, such as cancer and other chronic conditions, often face significant challenges when navigating the health care system. Learn about how professional navigators play a crucial role in identifying and addressing these challenges, a…

White Paper

Integrating ESR1 Mutation Testing into Oncology Practices

ESR1 mutations play a significant role in endocrine resistance in hormone receptor-positive, HER2-negative metastatic breast cancer. These mutations allow estrogen receptor alpha (ERα) to remain active, even in the presence of endocrine therapy, leading to disea…